Legend Biotech shares have plummeted nearly 50% in three months, erasing billions in market value and forcing investors to question whether the selloff is an overreaction or a prudent reassessment of the CAR-T leader's long-term prospects.
The U.S. Food and Drug Administration has removed a clinical hold on Intellia Therapeutics' pivotal Phase 3 study of its gene-editing candidate for a rare, progressive disease, allowing the trial to proceed with enhanced safety monitoring. The move refocuses investor attention on the company's pipeline and long-term valuation prospects.
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
Royal Philips is spearheading a significant European Union-backed consortium, PreciseOnco, aimed at advancing precision oncology through next-generation imaging and minimally invasive therapies. The move comes as the healthcare giant's stock performance draws mixed reviews from the market.
Biotech firm Perspective Therapeutics (CATX) has raised nearly $175 million in a follow-on equity offering, capitalizing on investor enthusiasm following promising early-stage data for its lead alpha-particle therapy candidate. The influx of cash alleviates immediate financial pressures but shifts the spotlight squarely onto upcoming clinical milestones and execution risks.
Amidst the blockbuster success of its weight-loss drugs, pharmaceutical giant Eli Lilly is making a strategic push into genetic medicine, securing exclusive rights to novel hearing loss treatments through a major partnership with German biotech Seamless Therapeutics.
Moderna forges a key partnership with Recordati to advance a therapy for propionic acidemia, while appointing a new Chief Development Officer as part of its strategic expansion beyond its COVID-19 vaccine roots.
The FDA launches a new program to fast-track reviews for strategically important drug manufacturing facilities. In separate developments, AstraZeneca faces a setback for a lupus drug formulation, while Acadia Pharmaceuticals receives a negative signal from European regulators for its Rett syndrome therapy.
Merck & Co. projected 2026 revenue below Wall Street expectations, citing a steeper-than-anticipated impact from patent expirations on key drugs like Januvia. The forecast overshadowed a strong Q4 performance driven by its blockbuster cancer therapy, Keytruda.
